Edition:
India

MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

48.80USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$48.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
131,025
52-wk High
$62.70
52-wk Low
$11.30

Chart for

About

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializi... (more)

Overall

Beta: --
Market Cap(Mil.): $1,434.94
Shares Outstanding(Mil.): 34.96
Dividend: --
Yield (%): --

Financials

BRIEF-MyoKardia Begins Dosing In Phase 2 MAVERICK-HCM Clinical Trial Of Mavacamten

* HCM TRIAL ARE ANTICIPATED IN SECOND HALF OF 2019 Source text for Eikon: Further company coverage:

02 Apr 2018

BRIEF-Myokardia Files For Potential Mixed Shelf Offering

* MYOKARDIA INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2FCACNv) Further company coverage:

09 Mar 2018

BRIEF-Myokardia Reports Q4 Loss Per Share Of $0.21

* MYOKARDIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

09 Mar 2018

BRIEF-Myokardia Begins Patient Dosing In Phase 1B Clinical Study Of Myk-491

* MYOKARDIA BEGINS PATIENT DOSING IN PHASE 1B CLINICAL STUDY OF MYK-491 IN DILATED CARDIOMYOPATHY PATIENTS

14 Feb 2018

BRIEF-MyoKardia Inc reports Q3 loss per share $0.42

* MyoKardia Inc reports third quarter 2017 financial results and operational progress

03 Nov 2017

Earnings vs. Estimates